Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.66 |
| ▸ | HTR3A | P46098 | 5/20 | 0.66 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.66 |
| ▸ | HTR3B | O95264 | 4/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305826 | 0.94 | CHRNA7 (0.57) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL7088010 | 0.93 | CHRNA7 (0.58) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL373178 | 0.90 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882150 | 0.89 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6874274 | 0.89 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL373195 | 0.89 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL373483 | 0.89 | CHRNA7 (0.85) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6884727 | 0.89 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL373704 | 0.89 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6882244 | 0.86 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592228-B2 | Treatment of inflammation using alpha 7 receptor-binding agonists | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2017-03-14 | — | — | US | claimed |
| EP-1581223-B2 | INHIBITION OF INFLAMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS | THE FEINSTEIN INST MEDICAL RES (US) | 2016-05-25 | — | — | EP | claimed |
| US-20150359785-A1 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING AGONISTS | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2015-12-17 | — | — | US | claimed |
| US-20130197028-A1 | nAChRalpha7 Agonists and nAChRalpha7 Antagonists for Treating Ulcerative Colitis (UC) and Crohn's Disease (CD) | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | claimed |
| WO-2011163539-A2 | nAChRα7 AGONISTS AND nAChRα7 ANTAGONISTS FOR TREATING ULCERATIVE COLITIS (UC) AND CROHN'S DISEASE (CD) | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-12-29 | — | — | WO | claimed |
| US-20110166148-A1 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-07-07 | — | — | US | claimed |
| EP-1581223-B1 | INHIBITION OF INFLAMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS | THE FEINSTEIN INST MEDICAL RES (US) | 2007-11-14 | — | — | EP | claimed |
| US-7273872-B2 | alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-09-25 | — | — | US | claimed |
| US-7238715-B2 | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2007-07-03 | — | — | US | claimed |
| EP-1581223-A2 | INHIBITION OF INFLAMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS | North Shore-Long Island Jewish Research Institute (US) | 2005-10-05 | — | — | EP | claimed |
| EP-1381603-A2 | QUINUCLIDINE-SUBSTITUEDARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2004-01-21 | — | — | EP | claimed |
| US-6492386-B2 | TREATING A DISEASE OR CONDITION IN A MAMMAL, WHEREIN THE ALPHA 7 NICOTINIC-ACETYLCHOLINE RECEPTOR IS IMPLICATED | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | claimed |
| US-6486172-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF BENZAMIDE OR BENZOCARBONYLSULFIDE SUBSTITUTED 1-AZABICYCLO(2,2,2)OCT-3-YL COMPOUNDS TO TREAT THE CONDITIONS ASSOCIATED WITH DEFECTS OF NICOTINIC SUBTYPES BRAIN RECEPTORS | PHARMACIA & UPJOHN COMPANY | 2002-11-26 | — | — | US | claimed |
| US-6479510-B2 | N-((2S,3R)-2-METHYL-1-AZABICYCLO(2.2.2)OCT-3-YL)-4-(4-HYDROXYP HENOXY)- BENZAMIDE FOR EXAMPLE; TREATING DISEASES OF THE ALPHA-7-NICOTINIC ACETYLCHOLINE RECEPTOR I.E. SCHIZOPHRENIA, OR PSYCHOSIS | PHARMACIA & UPJOHN COMPANY | 2002-11-12 | — | — | US | claimed |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | PHARMACIA & UPJOHN COMPANY | 2002-05-02 | — | — | US | claimed |
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-25 | — | — | US | claimed |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-04 | — | — | US | claimed |
| WO-2002016356-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016357-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
| WO-2002016358-A2 | QUINUCLIDINE-SUBSTITUTED ARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166148-A1 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING CHOLINERGIC AGONISTS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3A 916/4885HTR3E 1861/4885 |
| US-20020049225-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNA7 365/4885HTR3A 995/4885HTR3E 1415/4885 |
| US-20020040035-A1 | Quinuclidine-substituted aryl compounds for treatment of disease | UGT1A1, NAT1, SLC10A1 | CHRNA7 365/4885HTR3A 995/4885HTR3E 1415/4885 |
| US-20020052389-A1 | Treating a disease or condition in a mammal, wherein the alpha 7 nicotinic-acetylcholine receptor is implicated | CHRNA7, CHRNA1, CHRNB1 | CHRNA7 1/4885HTR3A 882/4885HTR3E 2024/4885 |
| US-20150359785-A1 | TREATMENT OF INFLAMMATION USING ALPHA 7 RECEPTOR-BINDING AGONISTS | CHRNA7, CHRNG, CHRNA1 | CHRNA7 1/4885HTR3A 642/4885HTR3E 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.